Target type: molecularfunction
Binding to a D1 dopamine receptor. [GOC:mah, GOC:nln]
D1 dopamine receptor binding is a crucial process in the nervous system, mediating the actions of dopamine, a neurotransmitter involved in a wide range of physiological and cognitive functions. The D1 receptor, a G protein-coupled receptor (GPCR), is activated by dopamine binding. This activation initiates a signaling cascade that ultimately leads to changes in neuronal activity.
The molecular mechanism of D1 receptor binding can be summarized as follows:
1. Dopamine binds to the D1 receptor, triggering a conformational change in the receptor's structure.
2. This conformational change activates the receptor's intracellular domain, which interacts with a G protein.
3. The G protein, specifically the Gs protein, is stimulated, leading to the activation of adenylyl cyclase.
4. Adenylyl cyclase catalyzes the conversion of ATP to cyclic AMP (cAMP), a second messenger molecule.
5. Increased cAMP levels activate protein kinase A (PKA).
6. PKA phosphorylates various intracellular proteins, leading to a cascade of downstream effects, including changes in gene expression, neuronal excitability, and synaptic plasticity.
D1 receptor binding plays a critical role in a wide range of physiological processes, including:
- **Motor control:** D1 receptor activation is essential for smooth and coordinated movement, as dopamine signaling via D1 receptors in the basal ganglia is involved in motor control.
- **Reward and motivation:** D1 receptor activation is implicated in the rewarding effects of drugs and natural rewards, playing a role in addiction and motivation.
- **Learning and memory:** D1 receptor activation facilitates learning and memory formation, particularly in the hippocampus, a brain region crucial for memory consolidation.
- **Cognitive function:** D1 receptor activation contributes to working memory, attention, and executive function, influencing higher cognitive processes.
Understanding the molecular function of D1 dopamine receptor binding is crucial for developing novel therapeutic strategies for various neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, and drug addiction.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas | A guanine nucleotide-binding protein G(s) subunit alpha (human), isoforms XLas-1, XLas-2, and XLas-3. [PRO:DAN, UniProtKB:Q5JWF2] | Homo sapiens (human) |
| Disks large homolog 4 | A disks large homolog 4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P78352] | Homo sapiens (human) |
| Prostaglandin E2 receptor EP1 subtype | A prostaglandin E2 receptor EP1 subtype that is encoded in the genome of human. [PRO:WCB, UniProtKB:P34995] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| ah 6809 | 6-isopropoxy-9-oxoxanthene-2-carboxylic acid: structure given in UD | xanthones | |
| dinoprostone | prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. | prostaglandins E | human metabolite; mouse metabolite; oxytocic |
| dinoprost | Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor. | monocarboxylic acid; prostaglandins Falpha | human metabolite; mouse metabolite |
| butaprost | |||
| cloprostenol | Cloprostenol: A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle. | prostanoid | |
| iloprost | iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension. Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation. | carbobicyclic compound; monocarboxylic acid; secondary alcohol | platelet aggregation inhibitor; vasodilator agent |
| tg4-155 | TG4-155: an EP2 receptor antagonist; structure in first source | ||
| 16,16-dimethylprostaglandin f2alpha | 16,16-dimethylprostaglandin F2alpha: RN given refers to (5Z,9alpha,11alpha,13E,15R)-isomer | ||
| u 62840 | U 62840: stereoisomeric benzindene prostaglandin analog; structure given in first source | carbotricyclic compound; carboxylic acid | antihypertensive agent; cardiovascular drug; human blood serum metabolite; platelet aggregation inhibitor; vasodilator agent; vitamin K antagonist |
| mk-0524 | MK-0524: a potent orally active human prostaglandin D(2) receptor 1 antagonist; structure in first source | indolyl carboxylic acid | |
| cp533536 | CP533536: an EP2 receptor-selective prostaglandin E2 agonist that induces bone healing; structure in first source | monocarboxylic acid | |
| ym-254890 | YM-254890: structure in first source | ||
| dg 041 | |||
| cj-042794 | aromatic ether | ||
| gw9508 | GW9508: structure in first source | aromatic amine | |
| cj-023,423 | grapiprant: a potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties; cyclooxygenase inhibitors | ||
| l-798106 | L-798106 : An N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of o-naphthalen-2-ylcinnamic acid with the sulfonamide group of 5-bromo-2-methoxybenzenesulfonamide. It is a selective antagonist for the prostanoid receptor EP3, a prostaglandin receptor for prostaglandin E2 (PGE2). | aromatic ether; bromobenzenes; N-sulfonylcarboxamide | prostaglandin receptor antagonist |
| cp 544326 | CP 544326: structure in first source | ||
| fr181157 | |||
| pf-04418948 | 1-(4-fluorobenzoyl)-3-(((6-methoxy-2-naphthyl)oxy)methyl)azetidine-3-carboxylic acid: structure in first source | ||
| cay 10580 | 2-(3-hydroxyoctyl)-5-oxo-1-pyrrolidineheptanoic acid : A pyrrolidin-2-one substituted by 6-carboxyhexyl and 3-hydroxyoctyl groups at positions 1 and 2, respectively. It is a potent prostaglandin EP4 receptor agonist (Ki=35 nM). CAY 10580: a E-prostanoid EP4 receptor agonist | hydroxy monocarboxylic acid; pyrrolidin-2-ones; secondary alcohol | prostaglandin receptor agonist |
| tat-nr2b9c | Tat-NR2B9c: a synthetic peptide consisting of the C-terminal 9 amino acids of the NR2B subunit of the NMDA receptor fused to the cell membrane protein transduction domain of the HIV-1-Tat protein | ||
| tg6-10-1 | TG6-10-1: brain-permeant prostaglandin E receptor 2 antagonist; structure in first source |